Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Twist Bioscience to Report Fiscal 2024 Second Quarter Financial Results on Thursday, May 2, 2024


Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, after market close on Thursday, May 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 4:30 p.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor Relations section under the "Company" tab at www.twistbioscience.com.

The conference call will be webcast live through the Investor Relations section under the "Company" tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on LinkedIn | X | YouTube | Instagram


These press releases may also interest you

at 18:39
Hillcore Group is very pleased to announce that they have completed the acquisition of Centurion Group's construction business, Centurion Canada Infrastructure, formerly SITE Resources Group ("SITE")....

at 18:37
Aktion Associates, Inc., a national software reseller and IT infrastructure provider focused on the Architectural Engineering & Construction, Distribution and Manufacturing industries, announces the acquisition of the Acumatica and legacy Sage...

at 18:30
Valaris Limited ("Valaris" or the "Company") today reported first quarter 2024 results. President and Chief Executive Officer Anton Dibowitz said, "I am very pleased with our start to 2024 as we delivered strong safety and operational performance...

at 18:25
Materion Corporation today reported first quarter 2024 financial results and provided an update to 2024 earnings guidance. Financial Summary Net sales were $385.3 million; value-added sales1 were $257.8 million Net income was $13.4 million,...

at 18:22
The Metropolitan Transportation Commission (MTC) and Lyft today kicked off National Bike Month by joining with partners from BART, the San Francisco Municipal Transportation Agency (SFMTA) and Daly City to cut the ribbon on a new Bay Wheels bikeshare...

at 18:21
Wajax Corporation ("Wajax" or the "Corporation") today announced its 2024 first quarter results. All monetary amounts are in Canadian dollars unless otherwise noted. Selected Highlights for the First Quarter First quarter revenue of $482.3 million...



News published on and distributed by: